Considering the induction of ZNF423 in ER+ BC with estrogen and its ability to induce BRCA1, future studies may concern an evaluation of the expression in specific types of BC as well as in ovarian cancer and if ZNF423 could be considered a useful biomarker or a therapeutic target in conjunction with SERMs or with PARP1 inhibitors. The gene discussed is ZNF423; the disease is ovarian carcinoma.